Industry
Biotechnology
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Loading...
Open
0.81
Mkt cap
52M
Volume
337K
High
0.84
P/E Ratio
-0.61
52-wk high
2.10
Low
0.75
Div yield
N/A
52-wk low
0.66
Portfolio Pulse from
November 07, 2024 | 3:15 pm
Portfolio Pulse from Benzinga Insights
October 04, 2024 | 4:32 pm
Portfolio Pulse from Avi Kapoor
September 18, 2024 | 9:58 am
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 11:52 am
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 11:45 am
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 11:27 am
Portfolio Pulse from Avi Kapoor
September 16, 2024 | 10:07 am
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 8:42 am
Portfolio Pulse from Avi Kapoor
September 03, 2024 | 6:59 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.